GB2600599B - Anti-Tau antibody and use thereof - Google Patents

Anti-Tau antibody and use thereof Download PDF

Info

Publication number
GB2600599B
GB2600599B GB2201160.5A GB202201160A GB2600599B GB 2600599 B GB2600599 B GB 2600599B GB 202201160 A GB202201160 A GB 202201160A GB 2600599 B GB2600599 B GB 2600599B
Authority
GB
United Kingdom
Prior art keywords
tau antibody
tau
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2201160.5A
Other languages
English (en)
Other versions
GB202201160D0 (en
GB2600599A8 (en
GB2600599A (en
Inventor
Yoon Seung-Yong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adel Inc
Original Assignee
Adel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adel Inc filed Critical Adel Inc
Publication of GB202201160D0 publication Critical patent/GB202201160D0/en
Publication of GB2600599A publication Critical patent/GB2600599A/en
Publication of GB2600599A8 publication Critical patent/GB2600599A8/en
Application granted granted Critical
Publication of GB2600599B publication Critical patent/GB2600599B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
GB2201160.5A 2019-07-15 2020-07-13 Anti-Tau antibody and use thereof Active GB2600599B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190085233 2019-07-15
PCT/KR2020/009207 WO2021010712A1 (ko) 2019-07-15 2020-07-13 항-타우 항체 및 이의 용도

Publications (4)

Publication Number Publication Date
GB202201160D0 GB202201160D0 (en) 2022-03-16
GB2600599A GB2600599A (en) 2022-05-04
GB2600599A8 GB2600599A8 (en) 2024-12-25
GB2600599B true GB2600599B (en) 2025-05-21

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2201160.5A Active GB2600599B (en) 2019-07-15 2020-07-13 Anti-Tau antibody and use thereof

Country Status (16)

Country Link
US (1) US20220204601A1 (enExample)
EP (1) EP4001305B1 (enExample)
JP (1) JP7595061B2 (enExample)
KR (1) KR102196840B1 (enExample)
CN (1) CN114430744B (enExample)
AU (1) AU2020313751A1 (enExample)
BR (1) BR112022000719A2 (enExample)
CA (1) CA3143811A1 (enExample)
CL (1) CL2022000087A1 (enExample)
GB (1) GB2600599B (enExample)
IL (1) IL289813A (enExample)
MX (1) MX2022000603A (enExample)
MY (1) MY207132A (enExample)
PH (1) PH12022550106A1 (enExample)
WO (1) WO2021010712A1 (enExample)
ZA (1) ZA202200724B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
WO2023039456A1 (en) * 2021-09-09 2023-03-16 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
KR20250010000A (ko) * 2022-05-27 2025-01-20 주식회사 진큐어 신규 펩타이드 및 그의 용도
CN115724967A (zh) * 2022-09-21 2023-03-03 天津鸿宇泰生物科技有限公司 一种识别Tau蛋白N端区域的单克隆抗体及其应用
JP2025540336A (ja) * 2022-12-08 2025-12-11 アデル，インク 抗タウ抗体及びペプチドを含む融合体とその用途
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
KR20150003274A (ko) * 2012-04-05 2015-01-08 에이씨 이뮨 에스.에이. 인간화된 타우 항체
KR20170106458A (ko) * 2015-02-26 2017-09-20 일라이 릴리 앤드 캄파니 타우에 대한 항체 및 그의 용도
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR20180072579A (ko) * 2016-12-21 2018-06-29 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
KR20150003274A (ko) * 2012-04-05 2015-01-08 에이씨 이뮨 에스.에이. 인간화된 타우 항체
KR20170106458A (ko) * 2015-02-26 2017-09-20 일라이 릴리 앤드 캄파니 타우에 대한 항체 및 그의 용도
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR20180072579A (ko) * 2016-12-21 2018-06-29 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Alzheimers & Dementia, Vol 12, 2016, Khanna et al, "Therapeutic strategies for the treatment of tauopathies: hopes and challenges" *
Brain, Vol 135, 2012, Irwin, et al, "Acetylated tau, a novel pathological signature in Alzheimer s disease and other tauopathies" *
NCBI. GenBank Accession No. ABK41140.1. immunoglobulin light chain varaible, partail [Mus musculus[. 14 July 2016. See entire document *
NCBI.GenBank Accession No. ACJ05297.1. immunoglobulin heavy chain variable region, partail [Mus musculus]. 26 July 2016. see entire document *

Also Published As

Publication number Publication date
IL289813A (en) 2022-03-01
CN114430744A (zh) 2022-05-03
MY207132A (en) 2025-01-31
EP4001305A1 (en) 2022-05-25
GB202201160D0 (en) 2022-03-16
WO2021010712A1 (ko) 2021-01-21
CA3143811A1 (en) 2021-01-21
JP2022541539A (ja) 2022-09-26
TW202116801A (zh) 2021-05-01
CN114430744B (zh) 2024-06-21
AU2020313751A1 (en) 2022-02-10
US20220204601A1 (en) 2022-06-30
KR102196840B1 (ko) 2020-12-30
BR112022000719A2 (pt) 2022-03-29
EP4001305B1 (en) 2026-07-01
EP4001305A9 (en) 2023-05-24
ZA202200724B (en) 2026-04-29
JP7595061B2 (ja) 2024-12-05
GB2600599A8 (en) 2024-12-25
PH12022550106A1 (en) 2022-11-21
EP4001305A4 (en) 2022-10-12
CL2022000087A1 (es) 2023-03-10
GB2600599A (en) 2022-05-04
MX2022000603A (es) 2022-05-20

Similar Documents

Publication Publication Date Title
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL290783A (en) Anti-tau antibodies and their uses
IL275737A (en) Variant antibodies against TIGIT
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL289813A (en) Antibody against tau and its use
SG11202100746WA (en) Anti-tigit antibody and use thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL289656A (en) Anti-tigit antibodies and their application
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL281297B2 (en) Anti-NPR1 antibodies and their uses
IL282708A (en) Anti-tim-3 antibodies and their use
IL277330A (en) Anti-IL-27 antibodies and uses thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL283926B1 (en) Antibodies against alpha-synuclein and their uses

Legal Events

Date Code Title Description
789A Request for publication of translation (sect. 89(a)/1977)

Ref document number: 2021010712

Country of ref document: WO

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20241223

Free format text: EXTENSION APPLICATION

Effective date: 20241219